Observational studyMedicine2026
Impact of etanercept on the progression of undifferentiated arthritis to rheumatoid arthritis: A prospective observational study in China.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study explores the association between tumor necrosis factor (TNF) antagonist therapy and the progression from undifferentiated arthritis (UA) to rheumatoid arthritis (RA). This single-center prospective observational real-world study enrolled 70 patients with UA (baseline score ≥ 8) at Xingtai People's Hospital (May-December 2020). After propensity score matching (1:1), 64 patients were matched; 4 lost to follow-up were excluded, leaving 60 for final analysis. Patients received MTX monotherapy or etanercept + MTX. Between-group differences were assessed using the Mann-Whitney U test, chi-square test, or Fisher exact test. Survival was analyzed using Kaplan-Meier curves and log-rank tests, and independent prognostic factors were identified through multivariable Cox regression. A total of 60 patients (30 per group) were included in the final analysis. During the 3-year follow-up, patients in the etanercept + MTX group had a significantly lower risk of progression to RA compared with the MTX monotherapy group (6/30 [20.0%] vs 14/30 [46.7%]; log-rank P = .012). After adjusting for potential confounders, combination therapy remained independently associated with reduced progression risk (HR = 0.28, 95% CI: 0.10-0.83, P = .022). Clinical remission at 3 years was achieved in 25 of 30 patients (83.3%) in the combination group, compared to 17 of 30 (56.7%) in the monotherapy group (P = .024). In this exploratory real-world observational study, initial treatment with etanercept + MTX was associated with a lower observed risk of progression to RA and a higher observed rate of clinical remission than MTX monotherapy in high-risk UA patients. These findings should be considered hypothesis-generating and require confirmation in adequately powered randomized controlled trials in diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.